PROFILING CIRCULATING DNA AND RNA TO IDENTIFY MECHANISMS OF THERAPEUTIC RESISTENCE AND RESPONSE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Grant number: 1098647 | Funding period: 2018 - 2020
Enzalutamide is a powerful hormone treatment that improves survival for men with advanced prostate cancer. Unfortunately, all prostate cancers eventually become resistant to enzalutamide and not all men initially respond to treatment. I will look for blood markers that predict which men benefit from enzalutamide treatment and try to understand how resistance to enzalutamide occurs. This may lead to more effective use of enzalutamide resulting in better outcomes in advanced prostate cancer.
Related publications (2)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke, Edmond M Kwan, Maria M Docanto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K Graham, Kate Mahon, Christine Hauser, Winston Tan, Xiao Hong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Pan Du, Jianjun Yu, Yong Huang, Shidong Jia, Manish Kohli, Lisa G Horvath, Arun A Azad
BACKGROUND: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profi..
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calven Wong, Pan Du, Shidong Jia, Siddhartha Yadav, Lisa G Horvath, Kate L Mahon, Edmond M Kwan, Heidi Fettke, Jianjun Yu, Arun A Azad
BACKGROUND: Metastatic prostate cancer is a clonally heterogeneous disease state characterized by progressive somatic perturbation..